Literature DB >> 17470525

Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction.

David Hallifax1, J Brian Houston.   

Abstract

The hepatic uptake of quinine, fluvoxamine, and fluoxetine (0.1-10 microM) was investigated with freshly isolated rat hepatocytes. The cell-to-medium concentration ratios (K(p)) were concentration-dependent: the mean maximum K(p) values (at 0.1 microM) were 150 (quinine), 500 (fluvoxamine), and 2000 (fluoxetine). There was also a large capacity site that was not saturable over the concentration range used (possibly partition into the phospholipid component of membranes); representing this site, the mean minimum K(p) values (at 10 microM) were 30 (quinine), 200 (fluvoxamine), and 500 (fluoxetine). To eliminate concomitant metabolism, cells were pretreated with the irreversible P450 inhibitor, aminobenzotriazole. The saturable uptake was substantially eliminated after exposure to carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (ATP inhibitor). The difference between the maximum and minimum K(p) for these three amine drugs, as well as for dextromethorphan, propranolol, and imipramine, was within a limited range of 3-fold, indicating a common magnitude of saturable uptake. Basic, permeable drugs are expected to be sequestered into lysosomes, which actively maintain their low internal pH (approximately 5) using ATP, and this process is predictable from the combined effects of pH-driven ion accumulation and unsaturable binding representing partition into membranes. The resultant predicted maximum K(p) correlated strongly with the observed maximum K(p). Thus, at low substrate concentrations, the fraction of drug unbound in the hepatocyte incubation (critical for assessing drug clearance and drug-drug interaction potential) may be dependent upon saturable as well as unsaturable binding, and for lipophilic, basic drugs, this can be readily estimated assuming a common degree of uptake into lysosomes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17470525     DOI: 10.1124/dmd.107.015131

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

1.  On the maintenance of hepatocyte intracellular pH 7.0 in the in-vitro metabolic stability assay.

Authors:  Leonid M Berezhkovskiy; Susan Wong; Jason S Halladay
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-11-01       Impact factor: 2.745

2.  Physiology-based IVIVE predictions of tramadol from in vitro metabolism data.

Authors:  Huybrecht T'jollyn; Jan Snoeys; Pieter Colin; Jan Van Bocxlaer; Pieter Annaert; Filip Cuyckens; An Vermeulen; Achiel Van Peer; Karel Allegaert; Geert Mannens; Koen Boussery
Journal:  Pharm Res       Date:  2014-07-22       Impact factor: 4.200

3.  Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.

Authors:  Eric J Lenze; Caline Mattar; Charles F Zorumski; Angela Stevens; Julie Schweiger; Ginger E Nicol; J Philip Miller; Lei Yang; Michael Yingling; Michael S Avidan; Angela M Reiersen
Journal:  JAMA       Date:  2020-12-08       Impact factor: 56.272

Review 4.  Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.

Authors:  X Chu; K Korzekwa; R Elsby; K Fenner; A Galetin; Y Lai; P Matsson; A Moss; S Nagar; G R Rosania; J P F Bai; J W Polli; Y Sugiyama; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2013-04-10       Impact factor: 6.875

5.  Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).

Authors:  Faraz Kazmi; Tiffini Hensley; Chad Pope; Ryan S Funk; Greg J Loewen; David B Buckley; Andrew Parkinson
Journal:  Drug Metab Dispos       Date:  2013-02-01       Impact factor: 3.922

6.  Strategies for Determining Correct Cytochrome P450 Contributions in Hepatic Clearance Predictions: In Vitro-In Vivo Extrapolation as Modelling Approach and Tramadol as Proof-of Concept Compound.

Authors:  Huybrecht T'jollyn; Jan Snoeys; Jan Van Bocxlaer; Lies De Bock; Pieter Annaert; Achiel Van Peer; Karel Allegaert; Geert Mannens; An Vermeulen; Koen Boussery
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

7.  Structural features determining the intestinal epithelial permeability and efflux of novel HIV-1 protease inhibitors.

Authors:  Lucia Lazorova; Ina Hubatsch; Jenny K Ekegren; Johan Gising; Daisuke Nakai; Noha M Zaki; Christel A S Bergström; Ulf Norinder; Mats Larhed; Per Artursson
Journal:  J Pharm Sci       Date:  2011-04-13       Impact factor: 3.534

8.  Measuring selective estrogen receptor modulator (SERM)-membrane interactions with second harmonic generation.

Authors:  Grace Y Stokes; John C Conboy
Journal:  J Am Chem Soc       Date:  2014-01-21       Impact factor: 15.419

9.  Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients.

Authors:  Johannes Matthaei; Jürgen Brockmöller; Werner Steimer; Konstanze Pischa; Stefan Leucht; Maria Kullmann; Ole Jensen; Typhaine Ouethy; Mladen Vassilev Tzvetkov; Muhammad Rafehi
Journal:  Front Pharmacol       Date:  2021-05-21       Impact factor: 5.810

10.  In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383.

Authors:  Ayşe Ufuk; Graham Somers; J Brian Houston; Aleksandra Galetin
Journal:  Pharm Res       Date:  2015-07-30       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.